– EOP 1004, Clinical StudyĪ Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial in Parallel Groups, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 12 to 30 Weeks to Patients with Clinically Significant Diabetic Macular Edema.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |